HRAS and urinary bladder carcinoma: To target bladder cancer tumors more specifically, cell surface antigens, such as fibroblast growth factor receptor 3, CD276, CD47 [48,49,50,51,52], or intracellular antigens, such as p53, TP63, isoforms of the Pi3-kinase, hRas, her2, and others, were considered [53,54].